Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma

Byung Woog Kang, Sang Kyun Sohn, Joon Ho Moon, Yee Soo Chae, Jong Gwang Kim, Soo Jung Lee, Won Seog Kim, Je Jung Lee, Se Ryeon Lee, Keon Uk Park, Ho Sup Lee, Won Sik Lee, Jong Ho Won, Moo Rim Park, Jae Yong Kwak, Min Kyoung Kim, Hyo Jung Kim, Sung Yong Oh, Hye Jin Kang, Cheolwon Suh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalBlood Research
Volume49
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Keywords

  • Chemotherapy
  • Epidemiology
  • Mantle cell lymphoma
  • Rituximab
  • Survival
  • Trend

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Kang, B. W., Sohn, S. K., Moon, J. H., Chae, Y. S., Kim, J. G., Lee, S. J., Kim, W. S., Lee, J. J., Lee, S. R., Park, K. U., Lee, H. S., Lee, W. S., Won, J. H., Park, M. R., Kwak, J. Y., Kim, M. K., Kim, H. J., Oh, S. Y., Kang, H. J., & Suh, C. (2014). Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma. Blood Research, 49(1), 15-21. https://doi.org/10.5045/br.2014.49.1.15